Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...
On March 2, 2026, Pierre Fabre Pharmaceuticals, Inc., submitted a request to the U.S. Food and Drug Administration (FDA) for a Type A meeting on the biologic license application for tabelecleucel, an ...
Resolution of Chronic Fatigue in a Patient With Post-COVID EBV Reactivation and Mold-Related Illness
Dr. Kasey Holland Hamski, ND A case illustrating the interplay between EBV reactivation, environmental mold exposure, and immune dysregulation in a patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results